TKNO logo

Alpha Teknova, Inc. Stock Price

NasdaqGM:TKNO Community·US$360.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

TKNO Share Price Performance

US$7.04
2.26 (47.28%)
US$7.00
Fair Value
US$7.04
2.26 (47.28%)
0.6% overvalued intrinsic discount
US$7.00
Fair Value
Price US$7.04
AnalystLowTarget US$7.00
AnalystConsensusTarget US$10.00
AnalystHighTarget US$12.00

TKNO Community Narratives

·
Fair Value US$7 0.6% overvalued intrinsic discount

Funding Gaps Will Hamper Biopharma Yet Resilience Will Emerge

1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value US$10 29.6% undervalued intrinsic discount

Automation And Biopharma Outsourcing Will Drive Market Expansion

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$12 41.3% undervalued intrinsic discount

Biopharma R&D And Cell Therapy Will Drive Custom Manufacturing

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$10
29.6% undervalued intrinsic discount
Profit Margin
14.21%
Future PE
80.69x
Price in 2028
US$12.35

Trending Discussion

No trending discussion available.

Updated Narratives

TKNO logo

TKNO: Reaffirmed 2026 Revenue Guidance Will Support Future Upside Potential

Fair Value: US$7 0.6% overvalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TKNO logo

Biopharma R&D And Cell Therapy Will Drive Custom Manufacturing

Fair Value: US$12 41.3% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TKNO logo

Automation And Biopharma Outsourcing Will Drive Market Expansion

Fair Value: US$10 29.6% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Adequate balance sheet and slightly overvalued.

2 Risks
2 Rewards

Alpha Teknova, Inc. Key Details

US$43.7m

Revenue

US$28.6m

Cost of Revenue

US$15.1m

Gross Profit

US$31.9m

Other Expenses

-US$16.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.31
34.60%
-38.37%
21.1%
View Full Analysis

About TKNO

Founded
1996
Employees
158
CEO
Stephen Gunstream
WebsiteView website
www.teknova.com

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company’ primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Recent TKNO News & Updates

Narrative Update Jun 25

TKNO: Reaffirmed 2026 Revenue Guidance Will Support Future Upside Potential

Analysts have adjusted their price target on Alpha Teknova to reflect updated assumptions around fair value at $7.00, a discount rate of 8.08%, revenue growth of 15.09%, a profit margin of 15.57%, and a future P/E of 47.22, citing these revised inputs as the key drivers of their refreshed outlook. What’s in the News for Alpha Teknova Alpha Teknova reaffirmed its revenue guidance for the fiscal year ending December 31, 2026, with expected total revenue in the range of $42 million to $44 million.

Recent updates

No updates